Clinical Pharmacokinetics of Quetiapine

  title={Clinical Pharmacokinetics of Quetiapine},
  author={C. Lindsay DeVane and Charles B. Nemeroff},
  journal={Clinical Pharmacokinetics},
Quetiapine is a dibenzothiazepine derivative that has been evaluated for management of patients with the manifestations of psychotic disorders. In pharmacokinetic studies in humans, quetiapine was rapidly absorbed after oral administration, with median time to reach maximum observed plasma concentration ranging from 1 to 2 hours. The absolute bioavailability is unknown, but the relative bioavailability from orally administered tablets compared with a solution was nearly complete.Food has… 

Comparative Physicochemical and Pharmacokinetic Properties of Quetiapine and Its Active Metabolite Norquetiapine.

NQTP administration results in increased systemic exposure and brain distribution compared to QTP administration, and future studies are needed to evaluate the pharmacologic and toxicologic effects of increased NQTP exposures.

Quetiapine in Overdosage: A Clinical and Pharmacokinetic Analysis of 14 Cases

It can be concluded that quetiapine intoxications appear to proceed mildly, and tachycardia and somnolence were the main clinical symptoms in the case series.

Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine.

Evidence is provided for a potent inhibition of quetiapine metabolism mediated by clarithromycin leading to a markedly reduced apparent oral clearance and a substantially prolonged terminal elimination half-life.

Pharmacokinetics and Tolerability of Extended-Release Quetiapine Fumarate in Han Chinese Patients with Schizophrenia

Quetiapine fumarate XR has a dose-proportional pharmacokinetic profile at doses ranging from 300 to 800 mg once daily, and a slower time to reach Cmax and steady state after 3 days of sequential dosing.

Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia

When quetiapine is co-administered with CYP3A inhibitors such as erythromycin, the dosing regimen should be modified according to quetuapine TDM.

Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia.

Quetiapine was absorbed quickly, distributed widely, and metabolized mainly to be quetiapsine sulfoxide, and gender had no effect on the pharmacokinetics of quetuapine and its metabolites.

Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications

Once-daily dosing and simpler dose titration makes using quetiapine XR convenient for clinicians and patients, and the impact of daytime sedation may be mitigated by evening dosing.

Bioequivalence of a Generic Quetiapine (Ketipinor®) in Healthy Male

Ketipinor® was bioequivalent to Seroquel ® in terms of both the rate and extent of absorption under fasting condition in both of which the reference product was within the acceptance range.

Pharmacokinetics of Quetiapine in Elderly Patients with Selected Psychotic Disorders

While quetiapine was well tolerated at doses up to 250mg three times daily, the potential for reduced clearance, as well as the adverse effects of postural hypotension and dizziness, indicated that it should be introduced at lower doses and titrated at a relatively slower rate in patients ≥65 years.



The Effect of Multiple Doses of Cimetidine on the Steady-State Pharmacokinetics of Quetiapine in Men With Selected Psychotic Disorders

No clinically relevant alterations in quetiapine pharmacokinetics were observed after cimetidine coadministration in patients with psychotic disorders, and the principal aim of the study was to investigate the effect of multiple doses of cimetine, a nonspecific P450 inhibitor, on the steady-state pharmacokinetic of quet iapine.

Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment

The Effects of Concomitant Phenytoin Administration on the Steady-State Pharmacokinetics of Quetiapine

D dosage adjustment of quetiapine may be necessary when the two drugs are given concurrently and that caution may be required when administering other drugs that inhibit or induce cytochromes, particularly P450 3A4.

Pharmacokinetic Interactions of Cimetidine 1987

Cimetidine reduces the renal clearance of drugs which are organic cations, by competing for active tubular secretion in the proximal tubule of the kidney, reducing the renal clearances of procainamide, ranitidine, triamterene, metformin, flecainide and the active metabolite N-acetylprocainamide.

Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders.

Quetiapine pharmacokinetics were dose proportional in adolescents and were similar to those previously reported for adults, well tolerated and effective in the small number of adolescents studied.

Effect of Fluoxetine and Imipramine on the Pharmacokinetics and Tolerability of the Antipsychotic Quetiapine

Combination therapy with quetiapine and fluoxetine or imipramine had a minimal effect on quetoapine pharmacokinetics and was well tolerated, and no statistically significant deterioration was observed for any item.

The Safety and Pharmacokinetics of Quetiapine When Coadministered With Haloperidol, Risperidone, or Thioridazine

Clinical stability can be maintained with good tolerability during the transition from quetiapine monotherapy to periods of coadministration with haloperidol, risperidone, or thioridazine.

A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia

The data support the atypical profile developed from preclinical studies and show that quetiapine is an effective, well tolerated antipsychotic that can be given twice daily.

Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel®) in patients with schizophrenia

PET data shows that quetiapine has a relatively low affinity for dopamine D2 receptors, with an occupancy half-life (10 h), which was about twice as long as that for plasma, which could suggest that the combination of D2/5HT2 receptor blockade contributes to the antipsychotic effect and a low incidence of EPS seen with quetuapine in comparative phase three trials.